Abstract |
The efficacy of BMS 180048, a 5-HT1 agonist in the acute treatment of a migraine headache, was evaluated in 216 patients. Three doses of the study drug were compared to placebo. Patients received a single test dose in the physician's office while being evaluated with a Holter monitor during a headache-free day. They then treated a migraines headache with a single dose of the study drug as an outpatient. The 150 mg- and 200-mg doses of BMS were significantly superior to placebo on change in pain intensity at 2 hours. Patients treated with BMS 180048 had a longer duration of response than placebo-treated patients. At the 24-hour point, only 24% of the 150-mg group and 25% of the 200-mg group had relapsed, compared to placebo which had a 42% relapse rate. It is concluded that BMS 180048 is an effective compound for the treatment of migraine headaches with a prolonged duration of response.
|
Authors | R E Ryan Jr, A Elkind, J Goldstein |
Journal | Headache
(Headache)
Vol. 37
Issue 4
Pg. 245-8
(Apr 1997)
ISSN: 0017-8748 [Print] United States |
PMID | 9150621
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Indoles
- Serotonin Receptor Agonists
- Sulfonamides
- Tryptamines
- avitriptan
|
Topics |
- Acute Disease
- Double-Blind Method
- Humans
- Indoles
(administration & dosage, therapeutic use)
- Migraine Disorders
(drug therapy)
- Salvage Therapy
- Serotonin Receptor Agonists
(administration & dosage, therapeutic use)
- Sulfonamides
(administration & dosage, therapeutic use)
- Time Factors
- Tryptamines
|